Evidence map›Paper›PMID 30971167›Full record

ArticleEpigenetics2019

Using NGS-methylation profiling to understand the molecular pathogenesis of young MI patients who have subsequent cardiac events.

Michelle Thunders, Ana Holley, Scott Harding, Peter Stockwell, Peter Larsen

Abstract read
In one paragraph

Article in Epigenetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Application of DNA Methylome Analysis to Patients with ME/CFS.Methods in molecular biology (Clifton, N.J.) · 2025
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Michelle Thundersa Department of Pathology (UOW) , University of Otago , Wellington , New Zealand.ORCID 0000-0001-6722-7072
Ana Holleyb Wellington Cardiovascular Research Group, University of Otago , Willington , New Zealand.
Scott Hardingc Department of Cardiology , Wellington Cardiovascular Research Group , New Zealand.
Peter Stockwelld Department of Biochemistry , University of Otago , Dunedin , New Zealand.
Peter Larsenb Wellington Cardiovascular Research Group, University of Otago , Willington , New Zealand.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Globally, ischaemic heart disease is a major contributor to premature morbidity and mortality. A significant number of young Myocardial Infarction (MI) patients (aged <55 y) have subsequent cardiac events within a year of their index event. This study used Next Generation Sequencing (NGS) methylation to understand the pathogenesis in this subset of young MI patients, comparing them to a cohort of patients without recurrent events. Cases and controls were matched for age, gender, ethnicity, and comorbidities. Differential methylation analyses were performed on Reduced Representation Bisulphite Sequencing (RRBS) data. Across the group and within case-control pairs' variation were analysed. Pairwise comparisons across each matched case-control pair resulted in a list of genes that were consistently significantly differentially methylated between all 16 matched pairs. This gene list was input into pathway analysis databases. Of particular relevance to cardiac pathology the following pathways were identified as over-represented in the patients with recurrent events; cell adhesion, transcription regulation and cardiac electrical conduction, specifically relating to calcium channel activity. This study looked at methylation differences between two populations of young MI patients. There were significantly different methylation profiles between the two groups studied; key pathways were identified as specifically affected in the patients with recurrent cardiac events. Matched pairwise comparisons and detailed interpretations of DNA methylation data may help to elucidate complex pathogeneses within and between clinical subtypes. Further analysis will determine whether these epigenomic differences can be useful as predictive biomarkers of clinical progression.

Indexed as

DNA MethylationEpigenesis, GeneticGene Expression RegulationBiomarkersCase-Control StudiesCohort StudiesFemaleHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedMyocardial InfarctionRecurrenceBiomarkersbiomarkerscardiacMethylationmyocardial infarctionnext-generation sequencingRRBSyoung

Identifiers

PMID30971167
PMCPMC6557607

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.